Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
The independent financial analyst theScreener just lowered the general evaluation of SHIONOGI (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date January 14, 2022, the closing price was JPY 7,489.00 and its target pri...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Int'l Equity Strategy In using technical analysis, we let the market be our guide. That is, we analyze what is true in the market, utilizing the vast array of tools in our technical analysis toolbox which we then formulate into our outlook using a weight of the evidence approach. In a world where there are no shortages of things to worry about (trade wars, central banks, Trump impeachment, negative interest rates, low global growth, Brexit, Manufacturing weakness, elections, Hong Kong protests,...
Pelham Smithers takes a look at Shionogi, examining the seemingly prevalent belief that earnings growth is set to slow considerably. He models for 9% CAGR to FY23 and in light of its reasonable valuations, he sees Shionogi's business and marketplace prospects developing favourably.
Defensive posture warranted Our outlook for global equity markets remains cautious and we expect additional weakness and consolidation, notwithstanding shorter-term countertrend rallies. Indexes throughout Europe and Asia continue their struggle to gain a firm footing, and, unsurprisingly, the same can be said of broad developed and emerging market indexes (i.e., MSCI EAFE, EM, ACWI, ACWI ex-U.S.) which are all in downtrends or have recently broken down. In light of continued global market weak...
PSA Today Feb 13: Japan Market Comment by Pelham Smithers, Joel Scheiman, William Nestuk and Thao Nguyen Nikkei ¥21,244.68 (-¥137.94/ -0.65%); Topix- ¥1,716.78 (-¥15.19 / -0.88%); ¥/$108.33 Tags: Shionogi (4507 JP), Roche (ROG SW), Gilead (GILD US), Astellas (4503 JP), Fujifilm (4901 JP), Xerox Corp (XRX US), Nabtesco (6268), Avex (7860 JP)Main Points at a Glance • Market slides as yen heads towards ¥107/$ • Kuroda reappointed BoJ Governor • Shionogi gains Japanese approval for baloxavir • Sony’...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.